

December 13, 2024

UPDATE: Product Allocations for U.S. IV Products – Hurricane Impact on Baxter’s North Cove, NC Facility

Dear Valued Customer:

In follow-up to Baxter’s communication on November 25, 2024 regarding increases in allocations for several U.S. IV products, we are pleased to share specific changes in allocation levels as described in this letter and in Tables 1 and 2 below. **These allocation increases will be effective December 17, 2024 and December 31, 2024 and are consistent for Baxter’s direct customers and distribution partners. Please note that there is a typical 1 to 2-week lag time for product to flow through the full distribution network after allocation changes are implemented.**

Due to the end of year timing, week 1 and week 2 allocations will be available to order on December 17, 2024. Week 3 allocation will be available to order on December 27, 2024. **Although allocations are available to order earlier, delivery timing will be dependent on various factors, which may impact the timing of fulfillment.**

If your facility is a designated children’s hospital or has received an approval through the pediatric allocation exception process, your allocation levels will not change. Allocation levels for 0.9% Sodium Chloride are increasing to 100% for Renal customers on December 17, 2024.

Baxter is increasing allocations as a result of 1) the current and projected status of our North Cove remediation efforts, 2) our expectations regarding our ability to reallocate capacity from other Baxter facilities, and 3) temporary importation of certain products.

Allocations for your facility are determined based on historical ordering from March 1, 2024 to August 31, 2024.

As seen in Table 1, the allocations, in some cases, refer to **groups of product codes**, meaning customers may receive a combination of product codes to reach the set allocation level for that product group.

Table 1: Product Groups with Assigned Allocation Levels, Codes, Descriptions, and NDCs

Product Group	Code	Description	NDC	Current Allocation Level	Current Allocation Level In Total	12/17 Allocation Level	12/17 Allocation Level In Total	12/31 Allocation Level	12/31 Allocation Level In Total
SODIUM CHLORIDE 0.9% INJECTION 1000ML	2B1324X	SOD CHLOR 0.9% INJ USP VIAFLEX 1000ML	0338-0049-04	80%	80%	100%	100%	100%	100%
0.9% INJECTION 500ML	2B1323Q	SOD CHLOR 0.9% INJ USP VIAFLEX 500ML	0338-0049-03	60%	90%	60%	100%	60%	100%
	UE1323	NACL 0.9% VIAFLO 500ML	0338-9543-03	30%		40%		40%	
SODIUM CHLORIDE 0.9% INJECTION 250ML	2B1322Q	SOD CHLOR 0.9% INJ USP VIAFLEX 250ML	0338-0049-02	60%	90%	60%	100%	60%	100%
	A6C1322US*	SODIUM CHLORIDE 0.9% 250ML IVINA	0338-9791-01	30%		40%		40%	

*Denotes Temporary Importation Code. The lot numbers of these Codes, which FDA authorized for importation and distribution by Baxter, are searchable on <https://meded.baxter.com/hurricane-helene-clinical-resources/baxter-resources-for-products-authorized-for-temporary-importation>

As seen in Table 2 on page 2, allocation levels are assigned to the Baxter U.S. product codes (which begin with “2B”) and not the temporary importation product code(s) denoted by an asterisk. Temporary importation product codes can be utilized as a substitute for their corresponding Baxter U.S. product codes. Please work with your Baxter representative if you would like to order temporary importation product codes.

Table 2: Product Groups, Codes, Descriptions, NDCs, and Allocation Levels

Product Group	Code	Description	NDC	Current Allocation Level	Current Allocation Level in Total	12/17 Allocation Level	12/17 Allocation Level in Total	12/31 Allocation Level	12/31 Allocation Level in Total
5% DEXTROSE INJECTION 1000ML	2B0064X	DEXTROSE 5% INJECTION USP VIAFLEX 1000ML MIGRATED	0338-0017-04	80%	80%	100%	100%	100%	100%
5% DEXTROSE INJECTION 500ML	2B0063Q	DEXTROSE 5% INJECTION USP VIAFLEX 500ML MIGRATED	0338-0017-03	80%	80%	100%	100%	100%	100%
5% DEXTROSE INJECTION 250ML	2B0062Q	DEXTROSE 5% INJECTION USP VIAFLEX 250ML MIGRATED	00338-0017-02	80%	80%	100%	100%	100%	100%
5% DEXTROSE +0.9% SODIUM CHLORIDE 1000ML	2B1064X†	5% DEXTROSE +0.9% SODIUM CHLORIDE 1000ML	00338-0089-04	40%	40%	40%	40%	40%	40%
	A6C1064US*	5% DEXTROSE +0.9% SODIUM CHLORIDE 1000ML		0338-9799-01		NA		NA	
LACTATED RINGERS INJECTION 1000ML	2B2324X	LACTATED RINGER INJECTION, USP VIAFLEX 1000ML	0338-0117-04	40%	40%	40%	40%	100%	100%
	JB2324*	SOLUTION, LACTATED RINGERS INJ VIAFLEX 1000ML	0338-9600-01	NA		NA		NA	
LACTATED RINGERS INJECTION 500ML	2B2323Q	LACTATED RINGER INJ, USP VIAFLEX 500ML	0338-0117-03	40%	40%	40%	40%	100%	100%
LACTATED RINGERS INJECTION 250ML	2B2322Q	LACTATED RINGER INJ, USP VIAFLEX 250ML	0338-0117-02	60%	60%	60%	60%	100%	100%
PLASMA-LYTE A INJECTION PH 7.4 1000ML	2B2544X	PLASMA-LYTE A INJECTION PH 7.4 MULTIPLE VIAFLEX 1000ML	0338-0221-04	60%	60%	40%	100%	40%	100%
	JB2544*	PLASMA-LYTE A INJ VIAFLEX 1000ML	0338-9591-01	NA		NA		NA	
	GCCE0324*	PLASMA-LYTE VIAFLO GCC 1000ML	0338-9593-01	NA		60%		60%	
0.9% SODIUM CHLORIDE IRRIGATION 3000ML	2B7127†	0.9% SODIUM CHLORIDE IRRIGATION USP VIAFLEX 3000ML UROMATIC	0338-0047-47	40%	40%	40%	40%	40%	40%
	JB7127*	0.9% SODIUM CHLORIDE IRRIGATION USP VIAFLEX 3000ML	0338-9834-01	NA		NA		NA	
	3KB7127*	0.9% SODIUM CHLORIDE IRRIGATION USP VIAFLEX 3000ML	0338-0110-01	NA		NA		NA	
LACTATED RINGERS IRRIGATION, 3000ML	2B7487	LACTATED RINGERS IRRIGATION USP VIAFLEX 3000ML ARTHROMATIC	0338-0137-27	40%	40%	40%	40%	100%	100%

*Denotes Temporary Importation Code. The lot numbers of these Codes, which FDA authorized for importation and distribution by Baxter, are searchable on

<https://meded.baxter.com/hurricane-helene-clinical-resources/baxter-resources-for-products-authorized-for-temporary-importation>

†Allocation level increase to 100% is expected mid-January.

Conservation efforts remain essential to supplement allocation levels. For medical information, support or questions regarding conservation strategies, please contact MedInfo@Baxter.com, call 1-800-933-0303, or visit [Hurricane Helene Conservation and Medical Information Resources | Baxter](#).

Thank you for your patience and partnership as we navigate this difficult situation.

Sincerely,

Mary Henson
General Manager, U.S. and Canada
Infusion Therapies and Technologies

Guillermo Amezcua
General Manager, U.S. and Americas
Kidney Care